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ABSTRACT
In response to injury, mature vascular smooth muscle cells (SMCs) undergo
dedifferentiation, also known as phenotype modulation or switch. This process is
characterized by a downregulation or loss of expression of contractile genes and
concomitant with an increase in cell proliferation, migration, and extracellular matrix
production, thereby leading to vascular lesion formation. However, the underlying
molecular mechanism is not fully understood. The objective of my study was to
determine whether cyclin-dependent kinase 8 (CDK8), a transcription-regulating kinase,
plays a mediator role in vascular SMC dedifferentiation and lesion formation. Our results
from immunochemical staining and Western blot revealed that CDK8 expression was
upregulated in vascular SMCs in mouse injured arteries and human arteries with
atherosclerosis. In cultured rat aortic SMCs (RASMCs), the dedifferentiated phenotype
exhibiting the downregulation of SMC contractile genes such as smooth muscle 22 alpha
(SM22α), calponin-1 (CNN1), and alpha smooth muscle actin (αSMA) as well as
increased proliferation, migration, and cytokine production was dramatically suppressed
and reversed into a more differentiated state by CDK8 inactivation via highly selective
CDK8 inhibitor, Senexin A, and shRNA knockdown approaches. Peri-vascular delivery
of CDK8 inhibitor, Senexin A attenuated ligation-induced neointima (NI) formation in
mouse carotid arteries. At the molecular level, we uncovered that CDK8 facilitated the
activation of AKT to inhibit GSK3β which phosphorylates c-MYC for degradation by
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proteasomes, thereby promoting vascular SMC dedifferentiation. In addition, activated
CDK8 formed signaling complex with AKT thereby activating AKT in vascular SMCs.
In conclusion, our results demonstrate that CDK8 is a critical mediator of vascular SMC
dedifferentiation at least partly by facilitating the AKT-mediated inhibition of GSK3β to
stabilize c-MYC, thereby contributing to NI formation. Targeting CDK8 may be a novel
therapeutic approach for the treatment of occlusive vascular disease due to the abnormal
growth of vascular SMCs.
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CHAPTER 1
THE HISTORY OF VASCULAR DISEASE AND CYCLIN-DEPENDENT
KINASE 8 FUNCTION
1.1 VASCULAR DISEASE:
Vascular disease is classified as an abnormality associated with the vascular
structure and function of blood vessels. There are several types of vascular diseases such
as atherosclerosis, restenosis, hypertension, and aneurysm. Although their fate differs,
these vascular diseases share are common pathological process, which are vascular
remodeling and the development of neointimal formation. This eventually results in the
occlusion of the blood vessel, which can lead to several complications. Vascular disease
is the world’s number one killer, accounting for 17.5 million deaths globally.1,2 The exact
cause of the disease is unknown, however, scientist and clinicians have identified factors
that can raise the risk for vascular disease. The major risk factors include unhealthy blood
cholesterol level, high blood pressure, smoking, insulin resistance, diabetes, obesity, and
physical inactivity. Age and family history have also been found to potentially influence
the onset of the disease.
Often, there are no signs or symptoms of vascular disease until the artery is
severely narrowed or occluded, by which time can cause heart attack or stroke. The signs
and symptoms vary depending on the artery affected, but can range from weakness,
paralysis, apnea, unconscious, and overall loss of cognitive function. Doctors diagnose
atherosclerosis by a physical examination, diagnostic tests, and/or family and medical
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history. Currently, there is no known cure for vascular disease, however there are a
number of medications that can be used to slow the progression of the disease. Such
medications include cholesterol medications, beta-blockers, angiotensin-converting
enzyme inhibitors, calcium channel blockers, and triamterene/hydrochlorothiazide (water
pills). In severe cases, the doctor may recommend surgical procedures such as
angioplasty, stent placement, or bypass surgery. However, these procedures are not a
permanent solution due to the re-narrowing on the artery, known as restenosis, and often
require a repeat procedure. Given the inadequacy of current medications and the
complications involving surgery, an extensive amount of research has been conducted to
develop new therapies for the treatment of vascular disease.

1.2 CELLULAR MECHANISMS OF VASCULAR DISEASE:
The structure and cellular composition of blood vessels are consistent throughout
the vascular system. However, there are certain features in the vasculature that vary and
reflect distinct functional requirements depending on their location. The basic cellular
components of a blood vessel consist of endothelial cells (EC), vascular smooth muscle
cells (VSMC), and extracellular matrix (ECM)—which are comprised of collagen,
elastin, and proteoglycans.
The vascular system is organized into three concentric layers: the tunica intima,
tunica media, and tunica adventitia, and is most distinctive in large vessels such as
arteries. The tunica intima is the innermost layer and comprised of ECs lining the lumen
of the vessel (known as the endothelium), a subendothelial layer that consist of
predominately connective tissue, and the internal elastic lamina, which separates the
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intima from the media layer. The tunica media, the middle layer, consist predominately of
VSMCs and external elastic lamina. VSMCs are responsible for vasoconstriction and
dilation of the blood vessel. The outermost layer, known as the tunica adventitia,
predominately consists of loose connective tissue, which is made up of fibroblasts and
collagen fibers, and small blood vessels (vasa vasorum).
Vascular disease involves the activation of many cell types including endothelial
cells, vascular smooth muscle cells (VSMCs), macrophages, mast cells, lymphocytes, and
neutrophils.3 Endothelial dysfunction is a primary event in vascular disease. Endothelial
cells are activated due to metabolic risk factors, thereby causing blood monocytes to
permeate the endothelial cell layer and infiltrate the intima and subintima layer of the
artery. During this process monocytes mature into macrophages resulting in their uptake
of lipids, yielding foam cells. VSMCs migrate from the media to the intima, proliferate,
secrete extracellular matrix (ECM), resulting a plaque formation. Necrosis of lipidcontaining foam cells and VSMCs result in a necrotic core formation. Dead and dying
cells accumulate in the region creating a fibrous cap, predominately composed of smooth
muscle cells and macrophages. The last step, thrombosis, involves the rupture of the
fibrous cap. Highly thrombogenic components of the necrotic core and tissue factors
come into contact with circulating monocytes in the blood, initiating a thrombus in the
vessel.
VSMCs exhibit a diverse range of phenotypes. In normal physiological
conditions, VSMCs are maintained in a quiescent “contractile” or differentiated
phenotypic state, which is necessary for contraction and dilation of the blood vessel.
During this quiescent state, VSMCs express a repertoire of VSMC markers, including
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smooth muscle cell myosin heavy chain (MYH11), calponin 1 (CNN1), smooth muscle
22 alpha (SM22α), and alpha smooth muscle actin (αSMA). These established VSMC
differentiation markers contain a CC(A/T-rich)6GG (CArG) element and a transforming
growth factor β (TGF-β) control element within the promoter/enhancer regions.
However, under pathological conditions, VSMCs will undergo a phenotypic transition
from quiescent state to a proliferative, non-contractile state or “synthetic” state. These
synthetic VSMCs will lose their expression of VSMCs markers, known as
dedifferentiation, and exhibit high rates of proliferation, migration and production of
ECM proteins and cytokines. This transition is known as a phenotypic modulation or
plasticity, and first originated in the 1960s from an ultrastructural characterization of
VSMC culture.4 In their synthetic state, VSMCs can migrate to the intima and proliferate
following vascular injury. The phenotypic modulation of VSMCs is a innate property of
differentiated VSMCs, which presumably evolved from higher species as an adaptation
for survival. However, an exorbitant degree of VSMC plasticity can result in adverse
vascular remodeling and disease. The synthetic phenotype of VSMCs, increased
proliferation, and increased migration and ECM secretion are key elements in lesion
formation. As such, a fine-tuning of VSMC phenotypic transition is necessary to regulate
the development and progression of vascular disease.
It is proposed that the dysfunction of vascular stem cells (VSCs) is essential in the
pathogenesis of vascular disease. An active state of adult VSCs may be an indication of
maladaptive vascular remodeling caused by the loss of quiescence and consequent
activation of VSCs. Therefore, a quiescent status of adult resident VSCs may be critical
for the repair of a damaged vasculature.5 The current understanding of adult resident
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VSCs is somewhat rudimentary. Adult resident VSCs are believed to originate from
embryogenesis. These cells are necessary for vascular development and remain within the
vasculature after birth for post-natal growth, aging and disease.6 These cells remain
quiescent until activated by vascular injury or disease. Given their close proximity, they
are quickly recruited to the site of injury for self-renewal and differentiation.7 These
stem/progenitor cells have very distinct phenotypes and appear in different compartments
in the vessel wall – the intima, media and adventitia. The characterization of these adult
resident VSCs remains unclear, due to the discrepancies in multiple reports. However,
what is clear is that these adult resident VSCs have the potential to differentiate to SMCs,
ECs, and pericytes. This is evident by their upregulation lineage specific cell markers
after stimulation with various growth factors and chemokines. In addition, these VSCs
have adipogenic, chondrogenic, osteogenic, leiomyogenic and angiogenic potential.
Although there are currently no established markers, Sca-1 is a primary marker used to
identify adult resident VSCs in the murine vasculature. Multiple reports also indicate that
these resident VSCs can contribute to vascular lesion formation rather than repair. Many
aspects regarding resident VSCs and progenitor cells remain to be addressed, such as
their profile, location, method of isolation, culture conditions, and animal injury models,
as well as the mechanisms that control their differentiation and function. A full evaluation
of adult resident VSC contribution to vascular remodeling cannot be performed without
considering all of these factors. Most importantly, addressing these aspects may connect
with the discrepancies in the multiple reports. Further investigation of molecular
mechanisms for controlling the functional states of resident VSCs may unravel the nature
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of resident VSCs per se as well as the precise contributions of VSC-mediated vascular
lesion formation and repair.

1.3 MOLECULAR MECHANISMS REGULATING VASCULAR SMOOTH MUSCLE
CELL PLASTICITY:
The phenotype modulation or plasticity of VSMCs plays a crucial role in the
development of vascular diseases. Therefore, the elucidation of the molecular
mechanisms regulating VSMC phenotypic modulation could provide some insight into
the development of vascular diseases. The phenotypic switching of VSMCs in vascular
disease is regulated by a multitude of environmental cues/signals, which will be
discussed in three categories: 1. Epigenetic mechanisms, 2. Genetic mechanisms, 3.
Protein quality control.
1. EPIGENETIC MECHNANISMS
A preceding level of regulation in SMC gene expression must occur to
account for the array of genes involved in the regulation of VSMC phenotype
modulation, rather than solely one gene. Transcriptional gene activation is
controlled by chromatin remodeling and histone modifications. This hierarchal
level of gene activation provides an additional layer of transcriptional control,
independent of RNA or DNA sequence, and is referred to as epigenetic
mechanism of gene regulation. An extensive amount of research has been
conducted to determine the epigenetic mechanism of VSMC phenotypic
modulation in vascular disease.
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Histones are a group of proteins that package DNA in nucleosomes. The
histone complex is an octamer which is assembled by two sets of protein-protein
interactions: H2A, H2B, H3, and H4. The acetylation of histones is a major
epigenetic mechanism in gene regulation. It involves the addition or removal of
acetyl groups from lysine residues on the histone N-terminal tails and is regulated
by histone acetyltransferases (HATs) and histone deacetylases (HDACs),
respectively. HATs add acetyl groups to histones, which promote chromatin
unfolding and make DNA more accessible for transcriptional gene activation.
HDACs reserve these effects by removal of acetyl groups from histones.
It was reported that HDAC transcription is increased in response to
mitogenic stimulation of VSMCs and is required for proliferation by regulating
G1-S phase cell cycle progression. HDAC inhibition induced cell cycle arrest by
preventing mitogen-induced retinoblastoma protein phosphorylation, and also
repressing mitogen-induced cyclin D1 mRNA expression and cyclin D1
transcription. Furthermore, HDAC inhibition reduced neointimal formation and
cyclin D1 expression following vascular injury.8
It has also been reported that acetylation at H3 and H4 residues are
enriched at SMC gene CArG boxes, and display high levels of H3 Lys4 and
Lys79 dimethylation (H3K4dMe and H3K79dMe, respectively) in SMCs relative
to non-SMC lineages.9 In conclusion, epigenetic modifications at the CArG
region represent an important site for the phenotypic modulation of VSMCs.
2. Genetic Mechanisms
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Serum response factor (SRF), a MADS box transcription factor, and its
co-activator myocardin bind to CArG boxes to initiate transcription of VSMC
genes in response to pathological environmental cues in culture and in vivo. It
was reported that myocardin interacted with H3K4dMe and selectively enhanced
SRF binding to CArG box chromatin of SMC genes, resulting in the upregulation
of SMC differentiation markers.9 Therefore, the control of SRF/myocardin
binding to CArG boxes represents a major mechanism in the phenotypic
modulation of VSMCs in vascular remodeling.
Krüppel-like factor 4 (KLF4) is a transcriptional repressor that has also
been found to play a role in the regulation of VSMC phenotype. KLF4 also acts as
a potent repressor of VSMC phenotype modulation by binding to the transforming
growth factor beta (TGF-β) control element within the promoter/enhancer regions
of VSMC differentiation markers.10 Furthermore, it interacts with SRF and
represses the expression of SRF co-activator myocardin and disrupt acetylation of
histone H4.9,11,12
Platelet-derived growth factor (PDGF) is a potent chemoattractant released
by activated platelets and many cell types including, ECs, macrophages, and
VSMCs from neointimal lesions. PDGF was shown to be a negative regulator of
VSMC markers, in vitro, and also stimulates VSMC proliferation and migration
by attenuating SRF/myocardin binding to VSMC CArG boxes. It was
demonstrated that KLF-4 is induced after PDGF-BB exposure. Also, suppression
of KLF4 by small interfering approach partially blocked PDGF-BB-induced SMC
gene repression. It was also determined that morphogen Sonic hedgehog (SSh)
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mediates PDGF-induced VSMC phenotypic modulation in cultured VSMCs
through regulation of KLF4.13 Taken together, these results suggest that KLF4
might act as key effector in PDGF-BB-induced repression of VSMC
differentiation markers.
Current studies are now aimed at determining the role of KLF4 in VSMC
phenotype modulation, in vivo. KLF4, which is not normally expressed in
differentiated SMCs, was rapidly upregulated in vivo in response to vascular
injury. This was the first evidence suggesting of KLF4 involvement in vascular
remodeling.12 Since KLF4 knockout mice result in early post-natal death14, SMCtargeted conditional KLF4 knockout mice were developed to determine the role of
KLF4 in vivo. It was shown that VSMC-specific conditional knockout of KLF4
markedly reduced lesion size, and increased fibrous cap thickness thereby causing
plaque stability.10 Therefore, the KLF4-dependent SMC phenotypic modulation
may be of critical importance the pathogenesis of vascular disease.
The deubiquitinating enzyme cylindromatosis (CYLD) is a critical
regulator of many cellular processes, via the regulation of nuclear factor kappa B
(NF-κB)-mediated inflammation. Our lab was able to demonstrate a novel role of
CYLD in mediating pro-inflammatory responses in VSMCs, via a NF-κBindependent manner. Knockdown of CYLD, by adenoviral approach, decreased
tumor necrosis factor alpha (TNFα)-induced pro-inflammatory cytokines
monocyte chemotactic protein-1 (Mcp-1), intercellular adhesion molecule
(ICAM-1) and interleukin-6 (IL-6) in rat aortic smooth muscle cells (RASMCs).
Furthermore, CYLD knockdown also suppressed TNFα-induced activation of
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mitogen activated protein kinases (MAPKs), extracellular signal-activated kinases
(ERK), c-Jun N-terminal kinases (JNK) and p38. Interestingly, CYLD expression
was increased in injured coronary artery afflicted with neointimal hyperplasia.15
Overall, these results suggest a pro-inflammatory role of CYLD in VSMCs via
MAPK activation and NF-κB-independent activation, thereby contributing to the
pathogenesis of vascular disease.
3. Protein Quality Control
Apoptosis is a process of programmed cell death that occurs during
normal development. Several environmental and endogenous factors have been
identified in the apoptosis of VSMCs in the development of vascular disease.
These factors include reactive oxygen and nitrogen species, cytokines, growth
factors, and oxidized lipoproteins. Other factors that play a role in the initiation
and progression of VSMC apoptosis include the Fas/Fas ligand/caspase deathsignaling pathway, Bcl-2 protein family/mitochondria, the tumor suppressive gene
p53, and the proto-oncogene c-Myc.
The Fas/Fas ligand/caspase death-signaling pathway plays an important
role in the in the induction of apoptosis in neointimal lesions. Both Fas/Fas
ligands have been shown to be expressed in neointimal VSMCs. Notably,
overexpression of Fas ligand, by adenovirus approach, was shown to inhibit
neointimal formation following balloon injury.16
The infiltration of immune cells within neointimal lesions also play a role
in the apoptosis of VSMCs. Immune cells, such as macrophages and T
lymphocytes, can produce inflammatory cytokines such as TNF and interferon-
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gamma (IFN-γ), which can secrete nitric oxide (NO), thereby inducing apoptosis
of VSMCs in cell culture. NO can attack iron-containing enzymes involved in
DNA synthesis and mitochondrial respiration, thereby leading to apoptosis of
target cells, such as VSMCs.17 It was demonstrated that macrophage-induced NO
can activate VSMC apoptosis via Fas ligand pathway. Human plaque derived
VSMCS underwent apoptosis when co-cultured with monocytes/macrophages.
However, this effect was inhibited by neutralizing antibodies to Fas ligand.18 In
addition, NO inhibitor blocked NO production by macrophages and reduced
VSMC apoptosis in response to macrophage induced NO.19
Tumor suppressive gene p53, and the proto-oncogene c-Myc were also
shown to be involved in VSMC apoptosis. Adenovirus-mediated transfer of p53
induced apoptosis which resulted in atherosclerotic plaque rupture.20 Fas itself has
also been shown to be mediated by p53. In addition, NO-induced apoptosis of
VSMCs include downstream mediators p5321 and Fas.22 It was also shown that
deregulated expression of c-Myc oncogene abolishes inhibition of proliferation of
VSMCs and induces apoptosis with various stimuli 23 Moreover, overexpression
of p53 induces apoptosis in rat VSMCs infected with c-MYC but not normal cells
24

Oxidized lipoproteins (OxLDL) can also induce VSMC apoptosis in
neointimal lesions thereby contributing to plaque instability and rupture. OxLDL
was localized to neointimal lesions as well as medial-derived VSMCs that
coexpress proapoptotic protein Bax.25 Consistent with this study, high OxLDL
can induce apoptosis of VSMCs via the Bax/Bcl-2 and lectin-like OxLDL
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receptor-1 in VSMCs.26 As such, the molecular mechanisms causing OxLDLinduced apoptosis may be involved in the destabilization and rupture of
atherosclerotic plaques.
Autophagy is another important physiological process, which results in the
destruction of cells by lysosomal compartments. While autophagy is necessary for
normal vascular function, it has also been found to play a role in vascular disease,
due to the dysfunction of SMCs.27 PDGF induces autophagy in VSMCS
independent of AMP-activated protein kinase (AMPK) and mammalian target of
rapamycin (mTOR). PDGF-induced autophagy also promoted the downregulation
of VSMC differentiation markers resulting in a synthetic phenotype, and
increased the proliferation and migration of VSMCs.28 SSh, which has already
been identified as a mediator in PDGF-induced VSMC differentiation, also
induced autophagy via protein kinase B (AKT) activation. Notably, treatment
with autophagy inhibitor 3-methyladenine, AKT inhibitor, or Shh receptor
cyclopamine significantly reduced neointimal formation in mouse carotid arteries
after ligation.29 Taken together, these results suggest a critical role of autophagy
in the pathogenesis of vascular disease due to the phenotype modulation of
VSMCs.

1.4 CYCLIN-DEPENDENT KINASE 8:
Cyclin-dependent kinases (CDKs) are traditionally characterized by their role in
cell cycle progression; however, there also exist a set of CDKs that are directly involved
in regulation of RNA polymerase II (RNAPII). These CDKs are known as transcriptional
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kinases. CDK8 exist within the family of transcriptional kinases. CDK8 is a part of the 30
subunit Mediator (MED) complex, which acts as a molecular bridge between DNAbinding transcription factors and RNAPII. The MED consists of the head, middle, tail,
and the CDK8 submodule. The head is composed of subunits MED6, MED8, 11, 17-20,
22, 28, the middle subunits are MED1, 4, 7, 9, 10, 14, 21, 26, 3/27, 31, the tail subunits
are MED15, 16, 23-25, 2/29. CDK8 consist within the CDK submodule consisting of
CDK8 (or its paralog CDK19), cyclin C, MED12 and MED13. It is well established that
MED is important for the pre-initiation complex since it interacts with RNAPII, thereby
influencing the transcription initiation process.
The MED complex also joins to transcription factors bound at upstream
regulatory elements such as nuclear receptors, and transcription machinery (RNAPII, the
general initiation factor TFIIA, -IIB, IID, IIE, IIF, and –IIH, DNA-binding transcription
factors) and transcription coactivators, at the promoter region, thereby controlling
epigenetic regulation, transcriptional initiation and elongation, transcriptional
termination, mRNA processing, noncoding RNA activation, and the chromatin
remodeling.30,31 Given its plethora of functions, the MED complex can be seen as a mass
coordinator of development and cell lineage determination. Several components of the
MED complex have been shown to cause embryonic lethality, such as MED1, MED12,
MED21, MED23, MED24, MED31 and CDK8.31 As such, gene knockdown approaches
of MED subunits have been employed to investigate MED deficiencies. Knockdown
mice or targeted inactivation of other subunits, such as MED1, MED12, MED14,
MED19, MED25, MED26 and MED28 and CDK8, indicated that these subunits play an
essential role in specific gene expression programs during differentiation and
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organogenesis. These subunits are also associated with cardiovascular diseases. Specific
MED subunits (MED1, MED12, MED13/13L, MED14, MED 15, MED23, MED25,
MED30, and CDK8) have been shown to be associated with congenital malformations,
such as congenital heart diseases.31 However, the precise role and interplay of Mediator
components and modules in cardiovascular pathologies still remain unclear. More
recently CDK8 has been shown to be a key component in the regulation of the MED
complex, making it a topic of interest.
CDK8 is a nuclear serine-threonine kinase that can regulate transcription. The
majority of evidence regarding CDK8 is based on its association with MED complex;
however, only a fraction of CDK8 exists outside of this complex. It has been proposed
that up to 30% of CDK8 can exist and function independently of the MED complex.
Biochemical analysis of recombinant CDK8 identified RNAPII and TFIIH, as well as
histone H3, MED13, and CDK8 as substrates for the CDK8 kinase. It was also revealed
that MED12, but not MED13, is essential for human CDK8 kinase activity.32,33
Furthermore, mass spectrometry analysis revealed CDK8 to be associated with DNA-PK,
GCN1L1 and TRiC chaperonin, which may help in controlling its biological function.32
However, the biological significance of DNA-PK, GCN1L1, and TRiC association
requires further elucidation.
Traditionally, CDK8 has been depicted as transcriptional repressor, however
much of this knowledge has been limited to research in yeast and metazoan cells. More
recent evidence demonstrates that CDK8 is also positive regulator in transcription.
Moreover, CDK8 has been shown to be a coactivator in many molecular pathways linked
to stem cells and cancer. These pathways include the β-catenin pathway, the p53
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pathway, the serum response network, the TGF-β signaling pathway, and thyroid
hormone-dependent transcription. Given its dual role in transcription, as a positive and
negative regulator, CDK8 can be deemed as a master regulator of transcription.
There are several reports of CDK8 as a negative regulator of transcription. The
most initial evidence of CDK8 as a co-repressor was shown in yeast. SRB10, the CDK8
homolog in yeast, was shown to phosphorylate the RNAPII CTD at Ser2 and Ser5 prior
to PIC assembly, thereby, inhibiting transcription.34 However, this has not been
confirmed in vivo and the mechanism remains to be elucidated.
SRB10 was also shown to inhibit transcription by promoting nuclear export or
degradation of specific transcriptional activators, such as Gcn4, the multistress response
transcriptional factor Msn2, and Ste2.35,36 SRB10 can phosphorylate Gcn4 marking it for
degradation by SCFCdc4 for ubiquitin ligase. Msn2 is also a substrate for SRB10 and is
translocated to the nucleus by heat-induced stress via hyper-phosphorylation in an
SRB10-dependent manner.35 Another substrate, Ste2, promotes the filamentous growth of
budding yeast Saccharomyces cervisiae in nutrient limiting conditions. SRB10 inhibits
filamentous growth via phosphorylation of Ste2, thereby decreasing its stability.
Furthermore, nitrogen limiting conditions resulted in loss of SRB10 protein, as well as
kinase activity, and corresponding loss of Ste2 phosphorylation.36 These results conclude
that SRB10 can employ a variety of regulatory mechanisms to coordinate gene
expression with growth potential.
Microarray results in yeast revealed that while most MED subunits play a positive
role through activator-mediated recruitment and interaction with RNAPII, the CDKmodule is predominately a negative regulator of transcription.37 These results reinforce
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this traditional view of CDK8 as an antagonist of transcription, at least in lesser organism
such as yeast.
In higher organisms, it was also demonstrated that human CDK8 can inhibit
transcription via phosphorylation and inactivation of the cyclin H subunit of TFIIH.38
Specifically, CDK8 phosphorylation of TFIIH phosphorylates mammalian cyclin H at the
amino-terminal and carboxy-terminal alpha-helical domains. This phosphorylation
repressed TFIIH to activate transcription and its CTD kinase activity.38
In addition, co-activation assays in vitro, demonstrated that human CDK8-MED is
less active than the core MED complex, and recombinant CDK module can block the
core MED co-activator function.39–41 However, it’s inhibition was independent of CDK8
activation, most likely due to MED12 and MED13 components.41 Furthermore,
compensatory mechanisms for gene activation involved less CDK8-Mediator and more
core-Mediator for MAPK-dependent activation of the transcription factor C/EBPβ, and
retinoic acid-induced activation of the RARβ2 gene.42,43
A previous study by Zhao et al reported that CDK8 and cyclin C are negative
regulators of lipogenesis in Drosophila and mammalian cells. CDK8 phosphorylation of
SREB-1c transcription factor at threonine residue (Thr) resulted in an increase in SREBP1c ubiquitination and protein turnover, thereby leading to inhibition of lipogenesis.44
While several reports indicate SRB10/CDK8 as a negative regulator in yeast, it is
also seen as a positive transcriptional regulator in yeast. For example, genome-wide
chromatin immunoprecipitation (ChIP) studies demonstrated that CDK8 was present in
active and inactivated genes, thus suggesting that CDK8 can promote transcription.45 It
was also shown that SRB10 phosphorylation of GAL4 at serine 699, is necessary for
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galactose-inducible transcription, and this transcription occurs concurrently with the
transactivation of general initiation factors.46 Furthermore, yeast CDK7 homolog, KIN28,
and SRB10 work together to promote RNAPII transcription and scaffold complex
formation by ATP-dependent dissociation of the PIC.47 This study also demonstrated
SRB10 phosphorylates two subunits of TFIID (BDF1 and TAF2) and KIN28
phosphorylates two subunits of MED complex (MED4 and MED14).47 In summary, the
aforementioned studies reveal SRB10/CDK8 is also as a positive regulator of
transcription in yeast.
In mammalians, CDK8 is a stimulus specific co-activator of p53-dependent
transcription.48,49 The p53 gene is a tumor suppressive protein involved in cell-cycle
arrest and apoptosis. The induction of cell-cycle arrest by p53 is activated by cyclindependent kinase inhibitor p21. Several studies have demonstrated that p21 is activated
by p53 upon Nutlin 3 treatment. Donner et al demonstrated that CDK8, along with cyclin
C and MED12, are recruited to p21 locus exclusively after Nutlin 3 treatment.49
Additionally, CDK8 recruitment correlates with positive transcriptional activity among
p53 target genes, Hdm2 and p21. RNA interference studies further confirmed that CDK8
is indeed a positive regulator of p53 target genes.49
CDK8 was also shown to be a positive regulator of thyroid hormone receptordependent transcription. Belakavadi demonstrated that CDK8 cooperates with MED
complex in thyroid hormone receptor-dependent transcription by promoting RNAPII
recruitment and activation of thyroid hormone-receptor target genes.50 It was further
demonstrated that CDK8 kinase activity is important for thyroid hormone dependent
transcription in vivo. ChIP assays revealed significant levels of CDK8 at the thyroid
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hormone receptor human type I deiodinase (DIOI) gene promotor during active
transcription. Additionally, CDK8 knockdown prevented thyroid hormone-dependent
activation of DIOI. Finally, CDK8 depletion was rescued with a wild type CDK8, but not
a kinase-dead mutant.50
It was also shown that CDK8 Enhances SMAD transactivation.33,48,51 TGF-β and
BMP receptor kinases activated SMAD transcription factors by C-terminal
phosphorylation, and subsequent translocation to the nucleus with SMAD4 where they
form transcriptional complexes of TGF-β- and bone morphogenetic factor (BMP)regulated genes. In the cytoplasm phosphorylation of receptor-activated SMADs in the
linker region led to proteasomal degradation.48 However, TGF-β and BMP activation led
to agonist-induced linker phosphorylation in the nucleus by CDK8 and CDK9. This was
due to CDK8 and CDK9 enhancement of receptor-activated SMADs by promoting coactivator recruitment.51
Recent studies indicate that CDK8 is a potential oncogene in colon cancer. Wnt/
β-Catenin signaling plays and important role in colon cancer.48,52,53 Upon activation, Wnt
signaling leads to stabilization of β-Catenin allowing its translocation to the nucleus and
formation of transcription complexes with TCF/LEF at Wnt-responsive genes such as
MYC and Cyclin D1. Loss of function studies identified CDK8 to be highly expressed in
human colon cancer cells. Suppression of CDK8 expression inhibited proliferation of
colon cancer cells while exhibiting high levels of CDK8 and β-Catenin hyperactivity.52
CDK8 was also found to associate with MYC promoter and knockdown of CDK8module subunits MED12 and cyclin C had a similar outcome to CDK8 knockdown,
suggesting that CDK8 collaborates with the CDK8-module to stimulate β-Catenin
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transcription.52 It still remains unclear whether CDK8 acts directly on the βCatenin/TCF/LEF complex or on the general transcriptional apparatus. CDK8 can also
play a role in β-Catenin activity through transcriptional factor E2F1. E2F1 is a
transcriptional regulator, which can promote proliferation and apoptosis. It was reported
that E2F1 represses β-Catenin transcription and is antagonized by CDK8
phosphorylation. Furthermore, both CDK8 and E2F1 were at the MYC promoter. 54
Overall, these results demonstrate the positive effects of CDK8 on β-Catenin
transcriptional activity, and its inhibitory effect on E2F1.
CDK8 promotes RNAPII elongation within the serum response network.
Mitogen-driven activation of the RAS/RAF/MEK/ERK pathway leads to transcription of
ELK1-dependent serum responsive genes.55 CDK8 promotes the recruitment of
transcription elongation factor, P-TEFb, providing a mechanism by which CDK8 can
positively affect transcription post-RNAPII recruitment steps.56
It was also revealed that CDK8 catalyzes histone modifications that correlate with
transcriptional activation. Biochemical assays revealed that cdk8-Mediator complex
associates with TRRAP and GCN5L polypeptides. Interestingly, the CDK8 and GCN5L
subunits within this ‘T/G-Mediator' complex work together to catalyze tandem
phosphoacetylation of S10/K14 within histone H3.57 Since tandem H3
phosphoacetylation correlates with active transcription, these results identify a role for
CDK8 in transcriptional activation.
The aforementioned studies support the role of CDK8 as positive and negative
regulator of transcription, from yeast to mammals. In summary, CDK8 was shown to be
involved in the regulation of transcription factor turnover, CTD phosphorylation and
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transcriptional activation or repression. CDK8 was also shown to regulate several
transcriptional programs involved in nutrient/growth factor sensors and differentiation
control, thus making it a potential therapeutic target.5
Alder et al demonstrated that CDK8 is required for tumor growth in vivo and
maintains tumors in a less differentiated state. Furthermore, CDK8 maintains embryonic
stem cell pluripotency, and this effect was partially mediated via the MYC pathway.58 In
this study, CDK8 inhibition resulted in little to no change in MYC mRNA levels,
suggesting that MYC is regulated post-transcriptionally. The regulation of MYC activity
involves priming the protein for degradation or transcriptional activation by
phosphorylation (p) on threonine 58 (T58) and serine 62 (S62), respectively.59,60 CDK8
inhibition by gene knockdown revealed an increase in the unstable MYC-pT58 and a
decrease in the active MYC-pS62, relative to total MYC. Exogenous expression of either
wild-type MYC or degradation resistant MYCT58A in embryonic stem cells increased
MYC levels compared to control cells and partially rescued the loss of embryonic stem
cell pluripotency imparted by CDK8 depletion. Conversely, expression of MYCS62A,
which disrupts the active phosphorylation site, increased total MYC levels but was
unable to rescue the loss in pluripotency, suggesting that CDK8 regulation of embryonic
stem cell pluripotency is partially mediated through MYC activity.58 Overall, these
results revealed that CDK8 might be positioned at a crossroad of tumorigenesis and stem
cell fate. It also raises the intriguing possibility that therapeutically targeting CDK8 may
inhibit the stem cell-like properties of cancer cells.
Porter et al recently discovered a small molecule inhibitor of CDK8 and its
isoform CDK19, though inhibition of p21-induced transcription.61 The inhibitor, known
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as Senexin A, inhibits CDK8 kinase activity by binding to the ATP pocket site. Of note,
Senexin A does not affect normal cell growth. Interestingly, the inhibitor was found to
suppress chemotherapy-induced tumor promoting paracrine activities of normal and
tumor cells. Moreover, the inhibitor also increased the efficacy of chemotherapy against
tumor cell xenografts. 61 Overall, these results identify CDK8 as a druggable mediator of
disease-promoting paracrine activities involved in DNA damage and senescence.
Therefore, CDK8 inhibition offers a potential therapeutic target for the inhibition of these
actions in cancer and other related diseases, such as vascular disease.
CDK8 resides upstream for transcription and therefore it might play a specific
role in coordinating genome expression in VSMC differentiation and remodeling. As
stated previously, some components of the MED complex have already been shown to be
involved in cardiovascular disease53 ; however, the extent of CDK8 involvement remains
to be determined. Based on these results, my overall hypothesis is that CDK8 is a critical
mediator in SMC dedifferentiation and vascular lesion formation. My aims are as
follows:
1. To explore the role of CDK8 in SMC dedifferentiation.
2. To determine the molecular mechanisms by which CDK8 regulates SMC
dedifferentiation.
3. To determine the role of CDK8 in SMC-mediated vascular remodeling in mice.
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CHAPTER 2
CYCLIN-DEPENDENT KINASE 8 IS A POSITIVE REGULATOR IN
VASCULAR SMOOTH MUSCLE CELL DEDIFFERENTIATON
2.1 INTRODUCTION:
Occlusive vascular disease, characterized by abnormal proliferation and
accumulation of vascular SMCs in the vascular lesion, is one of the most common causes
of morbidity and mortality in USA.62 Over the last decades, extensive studies including
the genetic inducible fate mapping experiments have convincingly supported a working
hypothesis that after vascular injury, mature and quiescent vascular SMCs undergo
dedifferentiation, also known as phenotype modulation or switch. This process is
characterized by a downregulation or loss of expression of contractile genes, such as
smooth muscle myosin heavy chain (MYH11), smooth muscle 22 alpha (SM22α),
calponin-1 (CNN1), and alpha smooth muscle actin (αSMA), and a concomitant with an
increase in cell proliferation, migration, and extracellular matrix (ECM) production,
thereby leading to vascular lesion formation.63–69 At the molecular level, mechanical
stress, a number of ligand-receptor interactions, and ECM-sensing machineries drive
intricate pathways at multiple levels of the gene expression regulation
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70–73

and/or the protein quality control74 thus contributing to vascular SMC

dedifferentiation. It is becoming clear, however, that these mechanisms are necessary for
complete control of vascular SMC physiology and pathophysiology. The master
regulators of vascular SMC dedifferentiation, which are druggable for the treatment of
vascular disease, remain to be determined.
CDK8 and its closely related paralog CDK19 (80% identical) are transcriptionregulating serine/threonine kinases with a functional overlap in the transcriptional
regulation.75 CDK8 is a component of the Mediator (MED) complex, which consists of
four distinct modules termed the head, middle, tail and CDK8 kinase module. In
mammals, Mediator complex has several subtypes with the most canonical one composed
of around 30 subunits to form the head (MED6, MED8, 11, 17-20, 22, 28), middle
(MED1, 4, 7, 9, 10, 14, 21, 26, 3/27, 31), tail (MED15, 16, 23-25, 2/29), and the
regulatory CDK8 module (CDK8/19, CCNC, MED12, and MED13) and joins
transcription factors bound at the upstream regulatory elements and the transcription
machinery (PolI, the general initiation factor TFIIA, -IIB, IID, IIE, IIF, and –IIH, DNAbinding transcription factor and transcription coactivators) at the promoter region,
thereby controlling epigenetic regulation, transcriptional initiation and elongation,
transcriptional termination, mRNA processing, noncoding RNA activation, and the
chromatin remodeling.30,48 Multiple approaches including gene knockout technology in
mice have revealed a general requirement for Mediator in coordinating the cell lineage
determination, development, and metabolism, which are potentially linked to
cardiovascular diseases.30,31 However, the precise role and interplay of Mediator
components and modules in cardiovascular pathologies are unclear. On the other hand,
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emerging evidence has indicated that CDK8 is not likely to regulate the expression of
stably expressed genes,48 and instead acts primarily to enable the elongation of
transcription of silent genes that become activated by transcription-induced
factors.51,52,56,76 In addition, CDK8 can indirectly regulate gene expression through
directly phosphorylating its protein substrates, such as receptor activated SMADs, E2F1,
STAT1, and p27, and likely independently of Mediator complex formation.51,54,76–79
Moreover, the conditional knockout of CDK8 throughout the body of adult mice does not
induce gross or histopathological abnormalities.80 These results indicate that CDK8operated signaling may not be essential for somatic cellular homeostasis, but play a
unique role in the pathological processes, such as the cell transformation for cancer61,
leading to diseases. Therefore, we questioned whether or not CDK8 is a yet unrecognized
regulator of vascular SMC dedifferentiation for occlusive vascular remodeling. In this
report, we demonstrate that CDK8 is a critical mediator of vascular SMC
dedifferentiation.
To investigate the role of CDK8 in SMC dedifferentiation, we used a primary
culture of rat aortic SMCs (RASMCs) and tested the effects of CDK8 inhibition by
utilizing a specific inhibitor of CDK8, Senexin A61, and lentivirus of CDK8 shRNA. We
also tested the effect of CDK8 overexpression by adenoviral approach. We hypothesized
that CDK8 inhibition will promote SMC differentiation by suppressing RASMC
proliferation, enhance SMC marker expression, and inhibit SMC migration and ECM
secretion. Conversely, CDK8 overexpression will promote SMC dedifferentiation by
increasing RASMC proliferation and decrease SMC protein marker expression. In the
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current study we demonstrate that CDK8 is a positive regulator of vascular SMC
dedifferentiation.

2.2 MATERIALS AND METHODS:
Animals:
Male Sprague Dawley (SD) rats (6-8 weeks old) were purchased from Jackson
Laboratories. All animals were housed at the AAALAC-accedited University of South
Carolina School of Medicine. All animal procedures were performed in accordance with
NIH Guideline for Care and Use of Laboratory Animals and were approved by the
Institutional Animal Care and Use Committee of University of South Carolina School of
Medicine.
Human Specimens:
Tissue sections of arteries were prepared from autopsy organ specimens of humans with
cardiovascular disease history (Appendix A.1). This study was approved by the
Institutional Review Board for human subject research at Icahn School of Medicine at
Mount Sinai, New York.
RASMC Isolation:
Briefly, SD rats were euthanized by intraperitoneal injection by an overdose of
pentobarbital (100 mg/kg) before tissue collection. The thoracic aortas were removed,
washed in phosphate-buffered saline (PBS) and incubated in 1g/L Dulbecco’s modified
Eagle’s medium (DMEM) containing 7.5 mg Collagenase type II (Worthington
Biochemical Corp. Cat. 17101-015) for 30 min. Using a dissection microscope, the
surrounding connective tissue and adventitia were removed. The dissected tunica media
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tissues were incubated for 2-3 hours with 7.5 mg Collagenase type II and minced
periodically throughout incubation. Cells were cultured in conventional regular growth
medium (RGM) containing 10% Fetal bovine serum (FBS) in DMEM and 100 μg/mL
penicillin/streptomycin in a 37 °C and 5% CO2 humidifed chamber.
Reagents and Antibodies:
The reagents used in this study were purchased as described below:
Senexin A/B from Senex Biotechnology (Columbia, SC), [H3] Thymidine (Cat #: 2403905, Millipore, Billerica, MA), Ad-Green fluorescent protein (GFP) (Cat#: 1060, Vector
Biolabs, Burlingame, CA), and Ad-c-Myc (Cat#: 1285, Vector Biolabs, Burlingame,
CA), Ecolite (Cat#:882475, Millipore, Bilerica, MA).
The following antibodies were purchased from Abcam (Cambridge, MA): c-MYC
(ab32072, GFP (ab6673), SM22α (ab14106), CNN1 (ab46974), αSMA (ab5694).
The following antibodies were purchased from Santa Cruz (Santa Cruz, CA): c-MYC
(sc40), Ubiquitin (sc-8017), JNK (sc571), CDK8 (sc1521).
The following antibodies were purchased from Sigma Aldrich (St. Louis, MO): B-actin
(a1978), GAPDH (a8795), αSMA (A5228), MYH11 (ab125884).
Quantitative real-time PCR (qPCR):
Total cellular RNA was purified with TRIzol (Invitrogen). Gene expression was
measured by qPCR, and normalized by concurrent measurement of glyceraldehyde 3phosphate dehydrogenase (Gapdh) mRNA levels. Primers for qPCR included SM22α 5’–
CCACAAACGACCAAGCCTTTT–3’ and 5’–CGGCTCATGCCATAGGATG–3’, Cnn1
5’–ACATCATTGGCCTACAGATG–3’ and 5’– CAAAGATCTGCCGCTTGGTG–3’,
Myh11 5’–CGGTGTTCTCCTGCTAGTCC–3’ and 5’–
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CTTCTTGGCTACCCAGTCGG–3’, Mmp2 (matrix metalloproteinase-2) 5’–
GACCTTGACCAGAACACCATCG–3’ and 5’–GCTGTATTCCCGACCGTTGAAC–3and Gapdh 5’–AGTGCCAGCCTCGTCTCATA–3’ and 5’–
GATGGTGATGGGTTTCCCGT–3’, OPN (Ostepontin) 5’–
AAGGCGCATTACAGCAAACACTCA–3’ and 5’–
CTCATCGGACTCCTGGCTCTTCAT –3’
Lentiviral Transfection:
pLKO.1 and CDK8 lentivirus was provided by Dr. Igor Roninson (University of South
Carolina School of Pharmacy, Columbia, SC). CDK8 lentivirus was generated as
previously described (Porter et al., 2012). Knockdown of CDK8 was generated by
transduction with pLKO.1 lentiviral vectors expressing the corresponding shRNAs (Open
Biosystems), followed by puromycin selection (2.5 μg/ml). The target sequences for
CDK8 shRNA was GTCTTATCAGTGGGTTGATTC.
Proliferation Studies:
Isolated RASMCs (p1-p10) were seeded at 10,000 cells/well on 24-well plate in RGM
with 10% FBS. Thereafter, RASMCs were serum starved for 16 hr. The following day,
RASMCs were treated with vehicle dimethyl sulfoxide (DMSO) 5 μm Senexin A/B for 0
- 9 days and proliferation was measured by a hemocytometer.
[H3]Thymidine Assay:
Isolated RAMCs (p1-p10) were seeded at 40,000 cells/well on a 24-well plate in RGM
with 10% FBS. Thereafter, RASMCs were serum starved for 16 hr. RASMCs were
treated with vehicle dimethyl sulfoxide (DMSO) 5 μm Senexin A for 24 hours, with
[3H]thymidine (1 μCi/ml) being added during the last 4 hours of culture. RASMCs were
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washed with ice cold 5% TCA overnight. The following day, RASMCs were washed
with ice cold 5% TCA, two times, and washed with 1x PBS, two times. RASMCs were
lysed with 0.5 ml of 0.5M NaOH for 30 min in a 37 °C and 5% CO2 humidifed chamber.
Cells were added to Ecolite (2ml/well). DNA synthesis was measured by [3H]thymidine
uptake via a liquid scintillation counter.
Differentiation Assay:
Isolated RASMCs (p1-p10) were seeded on 6-cm petri dishes in RGM with 10% FBS and
grown to 80-90% confluence. Thereafter, RASMCs were serum starved (DMEM alone)
for 16 hr. The following day, RASMCs were treated with the appropriate treatments for
48 hours. After treatment, RASMCs were subjected to Western blot analysis using SMC
differentiation markers.
Migration Assay:
Isolated RASMCs (p1-p10) were seeded on 6-cm petri dishes. RASMCs were serum
starved for 2 days, treated for the following three days. Treatments included 5 μm
Senexin A and 10% FBS. P200 pipet tip was used to create a scratch at the bottom of
each well and the cells were incubated further for 3 days. The distance between the edges
of the scratch was measured immediately after scratching and again after the time point
day 3. Migration was quantified and expressed as follows: % closure = [(distance
immediately after scratching – distance after 3 days)/distance immediately after
scratching] * 100. Microscopic pictures were taken using Infinity 3 microscope camera.
Western blot:
Protein extracts were prepared by standard procedures. Immunoblotting
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was conducted by enhanced chemiluminescence using Western Lightning Plus-ECL
(Perkin-Elmer).
Cell Cycle Analysis:
Isolated RASMCs (p1-p10) were seeded on 6-cm petri dishes in RGM with 10% FBS and
grown to 80-90% confluence (n=3 per treatment). Thereafter, RASMCs were serum
starved (DMEM alone) for 16 hr. The following day, RASMCs were treated with the
appropriate treatments for 48 hours. After treatment, cells were harvested by trypsin
method and subjected to flow cell cycle analysis. Briefly, RASMCs were centrifuged for
10 min at 1000 rpm at 25 °C in the medium. Media was aspirated. RASMCs were then
washed with 5 ml PBS and centrifuged for 10 min at 1000 rpm. Media was aspirated. 500
ul of ice-cold 70% ETOH was added dropwise. Samples were stored in -80 °C until
analysis. Cells were centrifuged at 1000 rpm for 5 min and ETOH was aspirated. 1 ml of
propidium iodine staining solution was added to cells on ice for 30 min. Samples were
then analyzed on Beckson Dickson Flow Cytometer. PI staining solution consisted of 200
ug/ml PI and 2mg/ml DNase-free Rnase A.
Statistics:
Data are shown as mean ± SEM. Differences between 2 groups were evaluated for
statistical significance using the Student t test when the sample size was appropriate and
the population was distributed normally. When differences among > 3 groups were
evaluated, results were compared by one-way ANOVA with Bonferroni test for multiple
comparisons. Differences were considered significant at p < 0.05.

2.3 RESULTS:
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Upregulation of CDK8 in Injured Arteries:
To explore a potential role of CDK8 in the vasculature, we examined the
expression pattern of CDK8 in mouse normal and injured arteries. Confocal microscopic
analysis revealed that CDK8 is mainly expressed in endothelial cells and media SMCs in
the normal carotid artery (Figure 2.1). However, the expression of CDK8 was increased
on 3 day and then decreased to near to the basal level on 28 day after complete carotid
ligation (Figure 2.2). In addition, the carotid ligation induced CDK8 expression in
adventitial cells with a similar pattern aforementioned (Figure 2.2). CDK8 expression
was also evident in NI cells on 28 day after the injury, although it was relatively low
(Figure IB). Western blot showed that CDK8 expression in the carotid artery was
increased on 3 day and then decreased to near to the basal level on 28 day after complete
carotid ligation (Figure 2.3). Since previous lineage-tracing studies have demonstrated
that the majority of NI cells are not derived from endothelial cells but mature vascular
SMCs68,81 and mature vascular SMCs undergo dramatic dedifferentiation on 3 day82 in
the carotid ligation model, these results suggest that CDK8 may play an important role in
the regulation of vascular SMC dedifferentiation and NI formation. Importantly, CDK8
expression was significantly upregulated in SMCs in the atherosclerotic plaque of human
carotid arteries (Figure 2.4). These findings highlight a pathological relevance of CDK8
in vascular disease.

A Mediator Role of CDK8 in Vascular SMC Dedifferentiation:
To investigate whether or not CDK8 regulates vascular SMC dedifferentiation,
we used a primary culture of rat aortic SMCs (RASMCs), a well-established culture
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system of dedifferentiated vascular SMCs.64 We found that SMC contractile proteins
including MYH11, αSMA, and CNN1 were dramatically downregulated in cultured
SMCs compared with SMCs in the tunica media, indicating a dedifferentiated state as
described elsewhere64 ; however, the CDK8 expression was significantly upregulated in
the dedifferentiated RASMCs (Figure 2.5). Inhibition of CDK8 activity via lentiviral
knockdown approach or a highly selective small molecule inhibitor of CDK8, Senexin
A61 attenuated cell number increases of RASMCs cultured in a full growth medium
(Figure 2.6) and FBS-induced [3H]-thymidine uptake in RASMCs (Figure 2.7) associated
with delayed progression through all phases of the cell cycle including G0/G1, S, and
G2/M phases (Figure 2.8) and increased expression of SMC contractile proteins including
αSMA, CNN1, and SM22α (Figure 2.9). The specificity of Senexin A was verified in
RASMCs (Figure 2.10). Senexin A treatment suppressed migration as well as the
expression of matrix metalloproteinase-2 (Mmp2) and osteopontin (Opn) while
upregulating the expression of SMC contractile proteins including Myh11, Cnn1, and
Sm22α in cultured RASMCs (Figure 2.11 and 2.12). These results demonstrate that
CDK8 is a critical mediator of vascular SMC dedifferentiation with typical synthetic
phenotypes including increased proliferation, migration, and secretion.

2.4 DISCUSSION:
CDK8 has been shown to be of importance in cancer cells and embryonic
cells.58,61 However, our results uncover, for the first time that CDK8 is normally
expressed in endothelial cells and vascular SMCs, thus suggesting that CDK8 is
expressed under normal physiological conditions in the vasculature. Moreover, CDK8
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was shown to be upregulated in dedifferentiating vascular SMCs suggesting that CDK8
may play a role in the pathological process of vascular disease. Mature vascular SMCs
undergo a dedifferentiation, also known as phenotype modulation or switch. This process
plays a critical role in vascular lesion formation and is characterized by a downregulation
or loss of expression of contractile genes and a concomitant with an increase in cell
proliferation, migration, and extracellular matrix production,.67,83 CDK8 inhibition was
able to regulate all three events by promoting increased proliferation, migration and ECM
secretion as well as promoting a synthetic phenotype. Therefore, we can conclude that
CDK8 acts as a mediator in SMC dedifferentiation and can potentially be a therapeutic
target in the treatment of vascular disease. Further studies are needed to investigate the
molecular mechanism by which CDK8 regulates SMC dedifferentiation as well as the
pathological relevance of CDK8, in vivo. Nonetheless, these results provide a significant
insight of the importance of CDK8 in the vasculature.
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Figure 2.1. CDK8 is expressed in media SMCs in normal carotid artery. Confocal
microscopic analysis of CDK8 in normal male adult mice in C57BL/6J background. L,
lumen; M, media.

Figure 2.2. CDK8 expression is upregulated after carotid ligation injury in mice. Male
adult mice in C57BL/6J background (n=10 for eac h group) were induced with cartoid
artery ligation and CDK8 expression was analyzed by confocal microscopy at day 3 and
day 28. The representative results are from 3 separate CDK8 stainings. L, lumen; M,
media.
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Figure 2.3. CDK8 protein expression is upregulated after carotid ligation injury in mice.
Male adult mice in C57BL/6J background (n=10 for each group) were induced with
cartoid artery ligation and CDK8 protein expression was analyzed by Western blot
analysis (upper panel) and protein bands were quantified using Image J Pro software
(lower panel).
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Figure 2.4. CDK8 is expressed in human coronary arteries with atherosclerotic lesions.
The images shown are representative of CDK8 staining in tissue sections of human
coronary arteries with atherosclerotic lesions (n=6). IEL, internal elastic lamina; EEL,
external elastic lamina; Ad, adventitia.

Figure 2.5. CDK8 protein expression is upregulated in RASMC cell culture. RGMcultured RASMCs at 11 days (passage 3) and the tunica media lysates (isolated from the
thoracic aorta of male SD rats at age of 10 weeks) were subjected to Western blot
analysis of CDK8 expression and SMC markers MYH11, αSMA, and CNN1.
Representative results are from 3 separate experiments.
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Figure 2.6. CDK8 inhibition reduced RASMC proliferation. A. Serum starved lentiviral
RASMCs were cultured in RGM for 0-9 days and proliferation was measured by a
hemocytometer (n=3). B. Serum starved RASMCs at early passage were cultured in 10%
FBS-supplemented media with 5 μm Senexin A for 0 – 9 days and proliferation was
measured by a hemocytometer (n=3).

Figure 2.7. CDK8 inhibition reduced DNA synthesis. A. RASMCs were lentivirally
transduced with scramble vector or shCDK8 and cultured in RGM. Serum starved
lentiviral RASMCs were treated as indicated for 24 h and subjected to [3H]-thymidine
uptake assay to measure DNA synthesis. B. RASMCs without lentiviral transduction
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were treated with 2.5µM and 5µM Senexin A for 24 h and subjected to [3H]-thymidine
uptake assay to measure DNA synthesis. n=6, *p<0.05 vs. control (-).

Figure 2.8. CDK8 inhibition prevented RASMC cell cycle progression at g0/g1 phase.
Serum starved RASMCs at early passage were treated as indicated for 48 h and subjected
to flow cytometry cell cycle analysis (n=3).

Figure 2.9. CDK8 inhibition promoted RASMC differentiation. A. RASMCs were
lentivirally transduced with scramble vector or shCDK8 and cultured in RGM. Serum
starved RASMCs were treated with 10% FBS for 10 minutes and subjected to Western
blot analysis of SMC protein markers (αSMA, CNN1 and SM22α) and CDK8. B. Serum
starved post-confluent RASMCs were stimulated with 10% FBS and 5 μM Senexin A for
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48 hours. Western blot was conducted to determine the expression of SMC protein
markers (αSMA and CNN1). Representative results are from 3 separate experiments.

Figure 2.10. Senexin A reduction on DNA synthesis is CDK8 specific. RASMCs were
lentivirally transduced with scramble vector or shCDK8 and cultured in RGM. Serum
starved lentiviral RASMCs were treated as indicated for 24 h and subjected to [3H]thymidine uptake assay to measure DNA synthesis. n=6, *p<0.05 vs. control (-).
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Figure 2.11. CDK8 inhibition attenuated FBS-induced migration of RASMCs. Serum
starved RASMCs at early passage were treated as indicated for 72 h and subjected to
migration assay. A. Pictures were taken via Infinity 3 microscope software. B. Migration
was quantified and expressed as follows: % closure = [(distance immediately after
scratching – distance after 72 h )/distance immediately after scratching] * 100 (n=3, *
indicates p<0.05).

Figure 2.12. Senexin A treatment increased extracellular matrix secretion. Serum starved
RASMCs (48 h) were treated with 20 ng/ml PDGF-ββ and 5 μM Senexin A (Sen A) for
24 h and qRT-PCR analysis was conducted to determine the relative mRNA expression
of contractile markers Myh11, Cnn1 and Sm22α and secretory markers Mmp1 and Opn
(n=3).
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CHAPTER 3
CYCLIN-DEPENDENT KINASE 8 IS A POSITIVE REGULATOR IN
VASCULAR SMOOTH MUSCLE CELL DEDIFFERENTIATION VIA
AKT/GSK3β-MEDIATED ENHANCMENT OF C-MYC
STABILIZATION
3.1 INTRODUCTION:
Occlusive vascular disease, characterized by abnormal proliferation and
accumulation of vascular SMCs in the vascular lesion, is one of the most common causes
of morbidity and mortality in USA.62 Upon vascular disease, SMCs will dedifferentiate
from a quiescent, contractile state with high expression of SMC markers to a
proliferative, synthetic state with low expression of SMC markers, thereby causing lesion
formation.63–69 This process is known as SMC dedifferentiation. At the molecular level,
mechanical stress, a number of ligand-receptor interactions, and extracellular matrixsensing machineries drive intricate pathways at multiple levels of the gene expression
regulation70–73 and/or the protein quality control74 thus contributing to vascular SMC
dedifferentiation. It is becoming clear, however, these mechanisms are necessary for
complete control of vascular SMC physiology and pathophysiology. The master
regulators of vascular SMC dedifferentiation, which are druggable for the treatment of
vascular disease, remain to be determined.
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CDK8 is a transcriptional kinase that has been involved in several regulatory
pathways. A recent study identified CDK8 as a druggable mediator of disease-promoting
paracrine activities involved in DNA damage and senescence. Therefore, CDK8
inhibition offers a potential therapeutic target for the inhibition of these actions in cancer
and other related diseases, such as vascular disease.
CDK8 inhibition resides upstream for transcription and therefore it might play a
specific role in coordinating genome expression in VSMC differentiation and
remodeling. In fact, our previous studies demonstrate that CDK8 is a positive regulator in
SMC dedifferentiation, resulting in increased cell proliferation and the downregulation of
SMC protein marker expression and an increase in FBS-induced migration and ECM
secretion. However, the molecular mechanisms that regulate CDK8-mediated SMC
dedifferentiation remains to be determined.
CDK8 has been shown to regulate several signaling pathways that are key
regulators in embryonic stem cell pluripotency, cancer, and presumably cardiovascular
disease.31,48,58,61 The oncoprotein c-MYC has been identified an important regulator in
tumor dedifferentiation and embryonic stem cell pluripotency. c-MYC resides
downstream of other target genes, which CDK8 has been shown to regulate. However,
upstream target genes of c-MYC have yet to be identified. It is possible that CDK8mediated SMC dedifferentiation is ultimately regulated by c-MYC. Therefore, we
hypothesized that CDK8 is a critical meditator of SMC dedifferentiation via the c-Myc
pathway.
To investigate the molecular mechanisms in CDK8-mediated SMC
dedifferentiation, we used a primary culture of rat aortic SMCs (RASMCs) and tested the
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effects of CDK8 inhibition by utilizing a specific inhibitor of CDK8, Senexin A61, and
lentivirus of CDK8 shRNA, and performed several signaling studies analyzed by Western
blot. We also tested the effect of c-MYC overexpression by adenoviral approach and
performed another set of signaling studies analyzed by Western blot. We hypothesized
that CDK8 plays a role in RASMC dedifferentiation via c-MYC pathway. In this report,
we demonstrate that CDK8 is an upstream operator of AKT/GSK3β signaling for c-MYC
stabilization leading to vascular RASMC dedifferentiation.

3.2 MATERIALS AND METHODS:
Animals:
Male Sprague Dawley (SD) rats (6-8 weeks old) were purchased from Jackson
Laboratories. All animals were housed at the AAALAC-accredited University of South
Carolina School of Medicine. All animal procedures were performed in accordance with
NIH Guideline for Care and Use of Laboratory Animals and were approved by the
Institutional Animal Care and Use Committee of University of South Carolina School of
Medicine.
RASMC Isolation:
Briefly, SD rats were euthanized by intraperitoneal injection by an overdose of
pentobarbital (100 mg/kg) before tissue collection. The thoracic aortas were removed,
washed in phosphate-buffered saline (PBS) and incubated in 1g/L Dulbecco’s modified
Eagle’s medium (DMEM) containing 7.5 mg Collagenase type II (Worthington
Biochemical Corp. Cat. 17101-015) for 30 min. Using a dissection microscope, the
surrounding connective tissue and adventitia were removed. The dissected tunica media
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tissues were incubated for 2-3 hours with 7.5 mg Collagenase type II and minced
periodically throughout incubation. Cells were cultured in conventional regular growth
medium (RGM) containing 10% FBS in DMEM and 100 μg/mL penicillin/streptomycin
in a 37 °C and 5% CO2 humidifed chamber.
Reagents and Antibodies:
The reagents used in this study were purchased as described below:
Senexin A/B from Senex Biotechnology (Columbia, SC), GSK3β inhibitor (SB-216763,
Cat#: S3442, Sigma-Aldrich, St. Louis, MO), AKT inhibitor (MK-2206, Cat#: 103235013-2, Sigma Aldrich, St. Louis, MO), Epoxomicin (Cat #: E3652, Sigma Aldrich, St.
Louis, MO), [H3], Ad-GFP (Cat#: 1060 Vector Biolabs, Burlingame, CA), and Ad-cMyc (Cat#: 1285, Vector Biolabs, Burlingame, CA).
The following antibodies were purchased from Cell Signaling Technologies (Beverly,
MA): pAKT T308 (CST 9275S), p-AKT S473 (CST 9271S), AKT (CST 9272S), AKT
(CST 2920), p-GSK3β (CST 9323P), GSK3β (CST 9315), p-ERK Thr202/Tyr04 (CST
9101S), ERK (CST 9102), p-JNK Thr183/Tyr185 (CST 9251), p-p38 Thr180/Tyr182
(CST 9211S), p38 (CST 9212), p-STAT1 Ser727 (9177), STAT1 (CST 9172).
The following antibodies were purchased from Abcam (Cambridge, MA): c-MYC
(ab32072), GFP (ab6673), SM22α (ab14106), CNN1 (ab46974), αSMA (ab5694),
MYH11 (ab125884).
The following antibodies were purchased from Santa Cruz (Santa Cruz, CA): c-MYC
(sc40), Ubiquitin (sc8017), JNK (sc571), CDK8 (sc1521)
The following antibodies were purchased from Sigma Aldrich (St. Louis, MO): B-actin
(a1978), GAPDH (a8795), αSMA (a5228).
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The following antibody was purchased from ProteinTech Group (Rosemont, IL): CDK8
(22067-1-AP).
Adenoviral Transfection:
Early passage (p) RASMCs (p1-p10) were transfected with Ad-GFP or Ad-cMyc
according to manufacturer’s protocol. 20 MOI of Ad-GFP or Ad-cMyc was added in SF
medium, and cells were incubated for 6 hrs in a 37 °C and 5% CO2 humidifed chamber.
Transfected cells were re-fed fresh media DMEM supplemented with 2% FBS. After 48
hours, the transfected cells were harvested by trypsinization and re-seeded on the
appropriate petri dishes for future studies.
Lentiviral Transfection:
pLKO.1 and CDK8 lentivirus was provided by Dr. Igor Roninson (University of South
Carolina School of Pharmacy, Columbia, SC). CDK8 lentivirus was generated as
previously described (Porter et al., 2012). Knockdown of CDK8 was generated by
transduction with pLKO.1 lentiviral vectors expressing the corresponding shRNAs (Open
Biosystems), followed by puromycin selection. The target sequences for CDK8 shRNA
was GTCTTATCAGTGGGTTGATTC.
Cell Signaling Studies:
Isolated RASMCs (p1-p10) were seeded on 6-cm petri dishes in RGM with 10% FBS and
grown to 80-90% confluence. Thereafter, RASMCs were serum starved (DMEM alone)
for 16 hr. The following day, RASMCs were treated with the appropriate treatments for
10 or 30 minutes. For some studies RASMCs were pre-treated with 0.1 μM Epoxomicin,
4 nM and 8 nM AKT inhibitor, or 0.01 μM GSK3β inhibitor for 1-2 hours. After
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treatment, RASMCs were subjected to Western blot analysis of potential signaling
pathways involved.
Proliferation Studies:
Isolated RASMCs (p1-p10) were seeded at 10,000 cells/well on 24-well plate in RGM
with 10% FBS. Thereafter, RASMCs were serum starved for 16 hr. The following day,
RASMCs were treated with vehicle control, dimethyl sulfoxide (DMSO), and 5 μm
Senexin A for 0 - 9 days and proliferation was measured by a hemocytometer.
[H3]Thymidine Assay:
Isolated RAMCs (p1-p10) were seeded at 40,000 cells/well on a 24-well plate in RGM
with 10% FBS. Thereafter, RASMCs were serum starved for 16 hr. RASMCs were
treated with vehicle dimethyl sulfoxide (DMSO) 5 μm Senexin A/B for 24 hours, with
[3H]thymidine (1 μCi/ml) being added during the last 4 hours of culture. RASMCs were
washed with ice cold 5% TCA overnight. The following day, RASMCs were washed
with ice cold 5% TCA, two times, and washed with 1x PBS, two times. RASMCs were
lysed with 0.5 ml of 0.5M NaOH for 30 min in a 37 °C and 5% CO2 humidifed chamber.
Cells were added to Ecolite (2ml/well). DNA synthesis was measured by [3H]thymidine
uptake via a liquid scintillation counter.
Differentiation Assay:
Isolated RASMCs (p1-p10) were seeded on 6-cm petri dishes in RGM with 10% FBS and
grown to 80-90% confluence. Thereafter, RASMCs were serum starved (DMEM alone)
for 48 h. The following day, RASMCs were treated with the appropriate treatments for 48
hours. After treatment, RASMCs were subjected to Western blot analysis using SMC
differentiation markers.
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Quantitative real-time PCR (qPCR):
Total cellular RNA was purified with TRIzol (Invitrogen). Gene expression was
measured by qPCR, and normalized by concurrent measurement of glyceraldehyde 3phosphate dehydrogenase (Gapdh) mRNA levels. Primers for qPCR include c-Myc 5’ –
TCCTCGCGTTATTTGAAGCCT-3’ and 5’–CGAGTCGTAGTCGAGGTCAT–3’, and
Gapdh 5’–AGTGCCAGCCTCGTCTCATA–3’ and 5’–
GATGGTGATGGGTTTCCCGT–3’.
Immunoprecipitation, Immunoblotting and Immunohistochemical Analyses:
The protein expression in cells and tissues were analyzed by immunoblotting and
immunohistochemical staining as we previously reported 83,84. The protein-protein
association in the cell was examined by immunoprecipiation and immunoblotting as well
as confocal microscopic analysis as we previously reported 83–85.
Statistics:
Data are shown as mean ± SEM. Differences between 2 groups were evaluated for
statistical significance using the Student t test when the sample size was appropriate and
the population was distributed normally. When differences among > 3 groups were
evaluated, results were compared by one-way ANOVA with Bonferroni test for multiple
comparisons. Differences were considered significant at p < 0.05.

3.3 RESULTS:
A Critical Role of CDK8 in Activating AKT/GSK3β Pathway and Stabilizing c-MYC in
Vascular SMCs:
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Recently, c-MYC and STAT1, the established mediators of vascular SMC
dedifferentiation,86–90 have emerged as downstream effectors of CDK8 in stem cells 58
and immune cells, respectively.78,79 Hence, we extrapolated these findings into cultured
RASMCs. We found that Senexin A did not affect STAT1 phosphorylation at Ser727, the
previously identified phosphorylation site of CDK8 in immune cells,78,79 but
downregulated c-MYC protein expression (Figure 3.1). The inhibitory effect of Senexin
A was further verified by lentiviral knockout of CDK8 (Figure 3.2). These results
indicate that c-MYC may be a downstream effector of CDK8 in mediating vascular SMC
dedifferentiation. Since CDK8 inhibition did not affect c-Myc mRNA expression level
(Figure 3.3) and could not lead to the downregulation of c-MYC anymore in the presence
of a proteasome inhibitor, Epoxomicin (Figure 3.4 and 3.5), it is most likely that CDK8
upregulates c-MYC expression via a posttranscriptional mechanism that stabilizes cMYC proteins in vascular SMCs.
It has been demonstrated that in the normal cell, c-MYC protein is rapidly
degraded following its synthesis with a half-life of ~20 min and the most prominent route
for c-MYC degradation is through the ubiquitin proteasome system (UPS).91 In addition,
the c-MYC degradation is regulated by multiple Ras effector pathways.91 The most
studied pathways are the Raf-MEK-ERK kinase cascade and the PI3K-AKT pathway that
inhibits GSK3β. The ERK and GSK3β phosphorylate two sites of c-MYC, i.e., Ser62 and
Thr58, respectively. The phosphorylation at Ser62 results in c-MYC stabilization. The
phosphorylation at Ser62 is also required for the subsequent phosphorylation of c-MYC
at Thr58 by GSK3β, which is associated with c-MYC degradation. Hence, we examined a
potential role of CDK8 in regulating the MAPK and AKT/GSK3β signaling for c-MYC
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stabilization in cultured RASMCs. Interestingly, not the serum-induced phosphorylation
of MAPKs including ERK, JNK and p38, but the phosphorylation of AKT and its
downstream effector GSK3β was inhibited by Senexin A (Figure 3.6). In addition, CDK8
inhibition led to increases in ratios of p-c-MYC (Thr58)/β-actin in both serum-starved
and serum-stimulated RASMCs (Figure 3.7). These results indicate that CDK8 promotes
the activation AKT to suppress GSK3β-mediated phosphorylation of c-MYC at Thr58 for
degradation in vascular SMCs.

A Novel Signaling Axis of CDK8-AKT Activation-GSK3β Inhibition-c-MYC
Stabilization for Vascular SMC Dedifferentiation:
Previous studies have shown that AKT and GSK3β may either promote or
suppress vascular SMC dedifferentiation and NI formation.92–95 Accordingly, we
determined the contribution of AKT and GSK3β to the CDK8 mediated stabilization of cMYC and phenotype modulation in cultured RASMCs. A dose-response study revealed
that AKT specific inhibitor MK-2066 (a highly selective inhibitor of AKT1/2/3 with
IC50 of 8 nM/12 nM/65 nM, respectively) at doses from 4 nM to 3 µM dose-dependently
suppressed FBS-induced phosphorylation of AKT (Thr308 and Ser473) and GSK3β
(Ser9) and upregulation of c-MYC (Figure 3.8 and Figure 3.9). MK-2066 (0.65 µM) also
inhibited FBS-induced cell number increases (Figure 3.10) as recently reported.96 The
Senexin A-induced suppression of AKT (Thr308) and GSK3β (Ser9) phosphorylation, cMYC expression, and increased proliferation were additively enhanced by MK-2066
(Figure 3.9 and 3.10). Like Senexin A, MK-2066 also inhibited FBS-induced
downregulation of CNN1 protein expression (Figure 3.11), which is in consistent with a
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recent report which shows AKT inhibitor induced suppression of vascular SMC
dedifferentiation in vivo.95 Moreover, MK-2066 and Senexin A additively suppressed the
FBS-induced downregulation of SMC contractile protein expression (Figure 3.11). These
results indicate that CDK8 is an upstream operator of AKT/GSK3β signaling for c-MYC
stabilization leading to vascular SMC dedifferentiation. To verify the notion, we used
GSK3β specific inhibitor SB-216763 (IC50, 0.343 µM) at a dose of 0.01 µM, which was
verified to maximally promote RASMC proliferation presumably due to the specific
suppression of GSK3β-induced c-MYC degradation (Figure 3.12). These results are
consistent with a previous report which shows GSK3β–dependent inhibitory effects on
vascular SMC proliferation and NI formation.93 Of note, the GSK3β inhibitor SB-216763
at doses from 0.01 µM to 25 µM was capable of upregulating AKT phosphorylation on
both Thr308 and Ser473; however, at effective doses lower than 1 µM, SB-216763
upregulated c-MYC protein levels while at the doses higher than 10 µM, it
downregulated c-MYC protein expression (Figure 3.12 upper and Figure 3.13). These
results indicate that GSK3β inhibitor SB-216763 at doses higher than 1 µM could not
inhibit GSK3β-mediated c-MYC degradation and instead may trigger c-MYC
downregulation via yet known off-target effects in vascular SMCs. In addition, GSK3β
acts as a negative regulator of AKT phosphorylation in vascular SMCs. Indeed, the
pharmacological inhibition of GSK3β-mediated c-MYC degradation attenuated the
inhibitory effect of Senexin A on c-MYC expression and cellular proliferation while
suppressing the Senexin A-induced upregulation of SMC marker expression (Figure
3.13-3.15). Moreover, the Senexin A-induced growth inhibitor effect and upregulation of
SMC contractile gene expression were also largely reversed by overexpression of c-MYC
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(Figure 3.16). To this end, our findings collectively demonstrate that CDK8 activates
AKT to suppress GSK3β-mediated c-MYC degradation thereby promoting RASMC
dedifferentiation.

An Inhibitor Role of CDK8 in AKT Subcellular Compartmental Translocation for
Activation in Vascular SMCs:
Although AKT signaling has been well implicated in vascular SMC biology and
pathology, the molecular mechanisms for AKT activation in vascular SMCs are largely
extrapolated from the other studies.97 Accordingly, it has been assumed that in response
to mitogen stimulation, AKT is translocated to the plasma membrane and then
phosphorylated on two key residues, Thr308 and Ser473, by 3-phosphoinositidedependent protein kinase-1 (PDK-1) and mammalian target of rapamycin complex 2
(mTORC2) respectively, leading to AKT activation. Following activation, AKT detaches
from the plasma membrane and translocates into the cytosol and nucleus to trigger its
downstream signaling. To explore whether or not CDK8 interrupts the aforementioned
signaling events for AKT activation in vascular SMCs, we determined a potential
interaction between CDK8 and AKT in cultured RASMCs by confocal microscopy as
well as immunoprecipitation (IP) and immunoblotting (IB) analyses. In the serum-starved
SMCs, AKT was expressed in the nucleus, cytosol, and membrane, whereas CDK8 is
expressed predominantly in the nucleus (Figure 3.17). Upon serum stimulation, AKT was
translocated to the plasma membrane and the nucleus; however, CDK8 was translocated
to the cytosol (Figure 3.17). Interestingly, inhibiting CDK8 activity via Senexin A (Sen
A) enhanced the cytosolic translocation of CDK8 while suppressing AKT membrane and
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nuclear translocation associated with AKT peri-nuclear accumulation (Figure 3.17).
Notably, CDK8 was co-localized with AKT in the nucleus and peri-nuclear region
(Figure 3.17). These results suggest that CDK8 physically associates with AKT to
promote its translocation to both the plasma membrane and nucleus thereby facilitating
AKT activation and AKT-driven signaling in vascular SMCs. Indeed, IP/IB studies
revealed that CDK8 associated with AKT in the serum-starved SMCs and the CDK8 and
AKT association was enhanced by serum stimulation; however, this association depended
on CDK8 activity (Figure 3.18). Collectively, these results demonstrate that CDK8 kinase
activity is critical for its association with AKT thereby activating AKT and AKT-driven
signaling in vascular SMCs.

3.4 DISCUSSION:
Our previous studies demonstrate a critical role of CDK8 in SMC
dedifferentiation with typical synthetic phenotypes including increased proliferation,
migration and ECM secretion; however, the molecular mechanism by which CDK8
regulates SMC dedifferentiation was not addressed. In the present study we identified a
novel signaling axis of CDK8-AKT activation-GSK3β inhibition-c-MYC stabilization in
mediating SMC dedifferentiation. We uncovered that: activation of CDK8 promotes the
activation AKT to suppress GSK3β-mediated phosphorylation of c-MYC at Thr58 for
proteasomal degradation in RASMCs; CDK8 activates AKT to suppress GSK3βmediated c-MYC degradation thereby promoting RASMC dedifferentiation; and CDK8
kinase activity is critical for its association with AKT thereby activating AKT and AKTdriven signaling in vascular SMCs.However, the precise mechanism by which CDK8
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mediates vascular SMC dedifferentiation was not completely delineated in this study.
Similar to Sen A drug treatment, AKT inhibitor MK-2066 (with IC50 of 8 nM/12 nM/65
nM, respectively) also inhibited FBS-induced downregulation of SMC markers CNN1 at
4nM dosage. Since the selected dosage was much lower than the recommonded IC50
dosage for AKT1 inhbition, it is mostly likely ATK1, can inhibit GSK3β-mediated cMYC degradation, thereby promoting vascular SMC dedifferentiation. Further studies
will need to be conducted to confirm the role of isoform AKT1 in SMC dedifferentation.
Moreover, the observed CDK8-c-MYC signaling axis may not be the sole mechanism for
facilitating vascular SMC dedifferentiation. Considering the observation that CDK8
primarily enabled the elongation of transcription of silent genes that become activated by
transcription-induced factors,51,52,56,76 usually in the pathological setting 98, it is possible
that CDK8 may also control the transcription of a group of genes for vascular SMC
dedifferentiation. Further investigation of these subjects will lead to a better
understanding of CDK8-mediated vascular remodeling.
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Figure 3.1. Senexin A treatment downregulated c-MYC protein expression but had no
effect on STAT1 phosphorylation. Serum starved RASMCs were treated with 10% FBS
and 5 μM Sen A for 30 min then subjected to Western blot analysis. Representative
results are from 3 separate experiments.

Figure 3.2. CDK8 inhibition by lentiviral approach reduced c-MYC protein expression.
Serum starved RASMCs were treated with 10% FBS and 5 μM Sen A for 30 min then
subjected to Western blot analysis. Representative results are from 3 separate
experiments.
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Figure 3.3. CDK8 inhibition did not affect c-Myc mRNA expression level. Serum starved
RASMCs (24 h) were treated with 10% FBS and 5 μM Sen A for 30 min then subjected
to qRT-PCR to determine relative c-Myc mRNA expression. Representative results are
from 3 separate experiments.

Figure 3.4. Senexin A treatment reduces c-MYC protein level of RASMCs by ubiquitin
proteasomal degradation. Serum starved RASMCs were pre-treated with proteasome
inhibitor, Epoxomicin at 0.1 μM, for 24 h and treated with 10% FBS and 5 μM Sen A for
30 min then subjected to Western blot analysis for c-MYC protein expression.
Representative results are from 3 separate experiments.
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Figure 3.5. The efficacy of Epoxomicin on proteasome function in cultured RASMCs.
Serum starved RASMCs were pre-treated with 0.1 μM Epoxomicin and 10% FBS for 24
hours then subjected to Western blot analysis. Representative results are from 3 separate
experiments.

Figure 3.6. The effect of CDK8 inhibitor Senexin A on FBS-induced activation of
MAPKs (ERK, JNK and p38) and AKT. Serum starved RASMCs were treated with 10%
FBS and 5 μM Sen for 10 minutes and subjected to Western blot analysis of potential
signaling pathways involved. Representative results are from 3 separate experiments.
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Figure 3.7. CDK8 inhibitor Senexin A increased c-MYC phosphorylation. Serum starved
RASMCs were treated with 10% FBS and 5 μM Sen for 30 minutes and subjected to
Western blot analysis. Representative results are from 3 separate experiments.
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Figure 3.8. The dose-response of AKT inhibitor (AKT-I) MK-2066 on FBS-induced
activation of AKT, inhibition of GSK3β, and upregulation of c-MYC. Serum starved
RASMCs were treated with 10% FBS and 5 μM Sen for 30 minutes and subjected to
Western blot analysis. Representative results are from 3 separate experiments.
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Figure 3.9. CDK8 inhibitor Senexin A and AKT inhibitor MK-2066 behave similarly in
FBS-induced activation of AKT/GSK3β pathway for c-MYC stabilization. Serum starved
RASMCs were treated with 10% FBS, 5 μM Sen, and 8 µM MK-2066 for 30 min and
subjected to Western blot analysis. The representative results are from 3 separate
experiments.
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Figure 3.10. AKT inhibitor, MK-2066, inhibited FBS-induced cell proliferation. Serum
starved RASMCs at were treated with 10% FBS, 5 um Senexin A, or 0.65 µM MK-2066
for 24 h and subjected to [3H]-thymidine uptake assay to measure DNA synthesis.
Representative results are from 3 separate experiments. n=3, #§<0.05 vs. 10%FBS (+)
alone.
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Figure 3.11. The effect of AKT inhibitor (AKT-I) and Senexin A on FBS-induced
downregulation of SMC contractile proteins. Serum starved RASMCs at were treated
with 10% FBS, 5 um Senexin A, and 4 nM MK-2206 (AKT-I) for 48 h and subjected to
Western blot. The upper panel shows representatives of immunoblots from 3 separate
experiments. The lower panel shows the semi-quantified results of CNN1 protein
expression. * p<0.05 vs. the control (-) in the same group.

Figure 3.12. GSK3β inhibitor (GSK3β-I) SB-216763 can dose-dependently regulate AKT
activity, GSK3 β activity, and c-MYC stability in cultured RASMCs, thereby affecting
RASMC proliferation. A. Serum starved RASMCs were treated in 10% FBS with
GSK3β-I at various dosages for 30 min and subjected to Western blot anaylsis of PI3KAKT signaling casade. B. Serum starved RASMCs were treated in RGM with various
dosages of GSK3β inhibitor (GSK3β-I) SB-216763 and the proliferation was measured
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by a hemocytometer. n=6, * p<0.05 vs. the 10%FBS + Vehicle control group at each
culture day.

Figure 3.13. CDK8 inhibitor Senexin A and GSK3β-I have opposing effects on FBSinduced activation of AKT/GSK3β pathway for c-MYC stabilization. Serum starved
RASMCs were treated with 10% FBS, 5 μM Sen, and 0.01 μM GSK3β-I (SB-216763)
for 30 min and subjected to Western blot analysis. Representative results are from 3
separate experiments.
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Figure 3.14. GSK3β inhibitor (GSK3β-I) SB-216763 increased FBS-induced cell
proliferation. Serum starved RASMCs at were treated with 10% FBS, 5 um Senexin A,
and 0.01 µM GSK3β-I (SB-216763) for 24 h and subjected to [3H]-thymidine uptake
assay to measure DNA synthesis. n=3, #§<0.05 vs. 10%FBS (+) alone.
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Figure 3.15. GSK3β inhibitor (GSK3β-I) SB-216763 and Senexin A have opposing
effects on FBS-induced downregulation of SMC contractile protein markers in cultured
RASMCs. Serum starved RASMCs were treated with 10% FBS, 5 μm Senexin A, and
0.01 µM GSK3β-I (SB-216763) for 48 h and subjected to Western blot. The upper panel
shows representatives of immunoblots from 3 separate experiments. The lower panel
shows the semi-quantified results of SM22α and CNN1 protein expression. * p<0.05 vs.
the control (-) in the same group.
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Figure 3.16. Adenoviral overexpression of c-MYC attenuated the effect of Senexin A
(Sen A) on RASMC proliferation and SMC contractile protein CNN1 expression.
RASMCs were adenovirally transduced with adenoviral GFP or adenoviral c-MYC and
cultured in RGM. A. Serum starved adenoviral RASMCs at were treated as indicated 3
days and measured by a hemocytometer (n=3). B. Adenoviral RASMCs were subjected
to Western blot analysis of GFP and c-MYC protein markers. C. Adenoviral RASMCs
treated with 10% FBS and 5 μM Sen A for 48 h and subjected to Western blot analysis.
Representative results are from 3 separate experiments.
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Figure 3.17. The effect of CDK8 inhibitor Senexin A on FBS-induced AKT membrane
and nuclear translocation. A. Serum starved RASMCs were treated with 10% FBS and 5
μM Sen A for 30 min and subject to confocal microscopy analysis. Typical confocal
microscopic images are representative of 3 separate experiments.
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Figure 3.18. The effect of CDK8 inhibitor Senexin A on FBS-induced AKT and CDK8
association. Serum starved RASMCs were treated with 10% FBS and 5 μM Sen A for 30
min then subjected to immunoprecipitation with AKT antibody followed by Western blot
analysis. The representative results are from 3 separate experiments.
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CHAPTER 4
CYCLIN-DEPENDENT KINASE 8-MEDIATED VASCULAR SMOOTH
MUSCLE CELL DEDIFFERENTIATION CONTRIBUTES TO
NEOINTIMAL FORMATION
4.1 INTRODUCTION:
Vascular disease remains to the leading cause of mortality in the United States
and worldwide.1,2 Neointimal formation (NI) is a key event in atherosclerosis and several
other vascular diseases. NI is caused by an abnormal increase in cell population within
the innermost layer of the arterial wall, resulting in a plaque formation that will
eventually occlude the vessel. The underlying causes of NI include SMC migration,
proliferation, and dedifferentiation.68,83 The neointima consists mainly of SMCs, however
myofibroblasts and fibroblasts have also been reported to contribute to the neointima.81
The carotid ligation surgery performed in mice has historically been used as a model to
study vascular disease.99 The neointimal SMCs that arise following carotid artery ligation
are largely derived from dedifferentiated vascular SMCs.63–65,67–69,81
Our previous studies indicate that CDK8 is a positive regulator in SMC
dedifferentiation via AKT/GSK3β-mediated enhancement of c-MYC stabilization. Due to
these results, we predicted that CDK8 might also play a role in vascular lesion formation.
To investigate the role of CDK8 in vascular lesion formation, we performed
carotid ligation surgery on mice and tested the effects of CDK8 inhibition in neointimal
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formation by utilizing a specific inhibitor of CDK8, Senexin A.61 We hypothesized that
CDK8 inhibition can reduce neointimal formation after carotid ligation surgery in mice.
In this report, we demonstrate that CDK8 is a critical mediator of vascular SMC
dedifferentiation and NI formation at least partly via its ability to facilitate activation of
the AKT/GSK3β/c-MYC stabilization signaling axis in vascular SMCs. Therefore,
targeting CDK8 may be a novel therapeutic approach for the treatment of occlusive
vascular disease due to the abnormal growth of vascular SMCs.

4.2 MATERIALS AND METHODS:
Immunoprecipitation, Immunoblotting and Immunohistochemical Analyses:
Immunoprecipitation, immunoblotting, and immunohistochemical staining were
performed as we previously reported.83,85,100 For confocal microscopic analysis of CDK8
and AKT expression and localization in vascular SMCs, RASMCs (P6-10) at 80%
confluent state were serum starved overnight prior to the treatment with vehicle DMSO
(0.2%, vol/vol) and 5 µM Senexin A (0.2% DMSO, vol/vol) in serum-free (SF) DMEM
or full growth medium for 30 min. These cells were then washed with ice-cold PBS twice
and fixed in 4% paraformaldehyde for 10 min at room temperature. After treatment with
0.01% triton X 100 for 1 min, all cells were incubated with 1% BSA at room temperature
for 1 h. Primary antibodies used were anti-AKT (Cat#: 2920, 1:200 dilution, Cell
Signaling), anti-CDK8 (Cat#: SC1521, 1:500 dilution, Santa Cruz Biotechnology) and
anti-AKT (Cat#: 2920, 1:200 dilution, Cell Signaling). Secondary antibodies used were
Alexa Fluor 488 (Donkey anti-Rabbit IgG (H+L) highly cross-adsorbed secondary
antibody, Cat#: A-21206, 1:500 dilution, Invitrogen) and Alexa Fluor 546 (Donkey anti-
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Mouse IgG (H+L) highly cross-adsorbed secondary antibody, Cat#: A-10036, 1:500
dilution, Invitrogen). The images were obtained under the same exposure condition. The
expression of CDK8 in tissue sections of human coronary arteries with atherosclerotic
lesions was also determined by confocal microscopic analysis using the antibodies above
mentioned. Fluorescent images were acquired using Zeiss LSM 510 META confocal
scanning laser microscope.
Carotid Ligation Model:
Male C57BL/6J mice at age of 12 wks were used for complete carotid artery ligation as
previously described.99 Briefly, the mice were anesthetized by intraperitoneal injection of
a solution of xylazine (5 mg/kg body weight) and ketamine (80 mg/kg body weight). The
left common carotid artery was dissected and ligated near the carotid bifurcation. At each
experimental end point, these mice were anesthetized with intraperitoneal injection of
pentobarbital sodium (50 mg/kg body weight) and euthanized by exsanguination. Blood
in the vessel was washed out by 0.9% NaCl perfusion for 5 min. The right carotid artery
was not ligated and served as an internal control for morphological measurement.
However, sham operated carotid arteries which were subjected to the same procedure
except for the ligation were used as the sham control for signaling dissection. This is
because in this mouse model, the complete ligation hardly induces neointimal hyperplasia
but does have impact on gene expression in the contralateral carotid artery.99,101 In an
effort to establish the complete carotid artery ligation model, we performed several sets
of experiments to characterize the complete ligation-induced inward remodeling in
carotid arteries. Whole carotid arteries were harvested at the experimental end points.
From the ligation point or carotid bifurcation (internal control), serial cross-sections (5-
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µm thick per section) were then cut in 5-mm length, resulting in 1000 sections per carotid
artery. Fifty sections located at 100-µm intervals from the ligation site or the carotid
bifurcation was sampled and numbered (100-µm × 50 = 5-mm) for each carotid artery.
We found that 30%~40% of ligated carotid arteries developed neointimal hyperplasia. In
addition, the intimal hyperplasia of the ligated carotid arteries (n=10) mainly occurred
within 2-3 mm of the vessel distal to the ligation site, which was maximal closest to the
ligation site, decreased in the thickness in the direction to the aortic arch, and disappeared
within the proximal 2-3 mm of the vessel adjacent to the aortic arch as previously
reported. 99Hence, the segments (~5-mm) from the ligation site or bifurcation to the
proximal site of the vessel adjacent to the aortic arch of sham-operated and ligated carotid
arteries (n=10) were excised and subject to Western blot analysis as previously
described.100 The contralateral (internal control) and ligated carotid arteries in a length of
1 mm from the ligation site or bifurcation to the aortic arch were subject to
morphological measurements of neointima formation, lumen patency, and cellular marker
expression. Briefly, after flushing out the blood, these arteries were fixed with 4%
paraformaldehyde under physiological pressure of 100 mmHg (13.3 kPa) for 10 min.
Whole left and right carotid arteries without the proximal ~2-mm of the vessel adjacent to
the aortic arch were harvested and further fixed with 4% phosphate-buffered
formaldehyde at 4°C for 24 h. The fixed arteries were embedded in paraffin or OCT for
sectioning. All carotid arteries were sectioned (5-µm thick per section) from the distal
end. We analyzed 5 sections located at 100-µm intervals from the ligation site or
bifurcation to the aortic arch of each control and ligated carotid arteries with or with
Senexin A treatment. These sections were subject to hematoxylin and eosin (H&E) or
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immunofluorescence staining. Nuclei were counterstained with 4,6-diamidino-2phenylindole (DAPI). The primary antibody for CDK8 staining was anti-CDK8 (Cat#:
22067-1-AP, 1:500 dilution, Proteintech). The images were obtained under the same
exposure condition. Fluorescent images were acquired using Zeiss LSM 510 META
confocal scanning laser microscope.
Drug Treatment:
Senexin A was delivered locally as follows: Senexin A (30 µM/L) or vehicle control
DMSO (0.3%, vol/vol) in 100 µl 20% Pluronic F-127 gel (Cat: BCBH4538V, SigmaAldrich) was delivered to the adventitia of ligated arteries immediately after ligation.
Statistics:
Data are shown as mean ± SEM. Differences between 2 groups were evaluated for
statistical significance using the Student t test when the sample size was appropriate and
the population was distributed normally. When differences among > 3 groups were
evaluated, results were compared by one-way ANOVA with Bonferroni test for multiple
comparisons. Differences were considered significant at p < 0.05.

4.3 RESULTS:
A Mediator Role of CDK8 in Vascular SMC Dedifferentiation and NI formation in vivo:
Our in vitro results encouraged us to examine the pathological relevance of the
CDK8 signaling in vivo. Using a mouse model of NI formation in the carotid artery
induced by complete ligation in which the majority (~80%) of NI cells is derived from
mature vascular SMCs,81 we found that peri-vascular delivery of Sen A (30 µM/L) in
20% Pluronic F-127 gel immediately after ligation procedure dramatically suppressed the
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activation of AKT and the upregulation of c-MYC while reversing the downregulation of
SMC markers such as αSMA, CNN1, and SM22α on 3 day after ligation (Figure 4.1),
and significantly inhibited SMC accumulation in the NI (Figure 4.2) and NI formation 28
day post-ligation (Figure 4.3). These findings reveal a potential role of the newly
identified CDK8/AKT/GSK3β/c-MYC stabilization-signaling axis in mediating vascular
SMC dedifferentiation and NI formation (Figure 4.4).

4.4 DISCUSSION:
Our previous studies uncover for the first time a novel signaling axis of CDK8AKT activation-GSK3β inhibition-c-MYC stabilization in mediating vascular SMC
dedifferentiation, thus providing new insight into the pathogenesis of occlusive vascular
disease associated with SMC dedifferentiation. Because of the firmly established concept
that the abnormal growth and accumulation of dedifferentiated vascular SMCs largely
contribute to vascular lesion formation,63–65,67–69,81 most of the therapeutic approaches for
vascular diseases, in particular occlusive vascular disease, have focused on either direct
or indirect inhibition of SMC proliferation in diseased vessels such as failing vein grafts
.102,103 However, none of them are truly effective, thus the 10-year vein graft failure rates
(~50%) have remained largely unchanged over the last two decades.102,103 The underlying
reasons may be multifactorial, but a plausible interpretation is that the master regulators
of vascular SMC dedifferentiation are still missing. In this regard, our serial findings
indicate that CDK8 may be such a regulator. Firstly, we demonstrated that inactivation of
CDK8 led to the suppression of vascular SMC dedifferentiation with typical synthetic
phenotypes including increased proliferation, migration, and ECM secretion in vitro.
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Secondly, we established that inactivation of CDK8 inhibited SMC accumulation in NI
and NI formation of ligated carotid arteries, in which the majority (~80%) of NI cells is
derived from mature vascular SMCs.81 Finally, we further confirmed the critical role of
CDK8 in mediating the vascular SMC-dependent NI formation in other models of
occlusive vascular remodeling, i.e., the transplantation of isologous jugular veins and the
transplantation of decellularized aorta scaffolds in which we verified a major contribution
of mature vascular SMCs to NI formation by genetic inducible fate mapping approach 104
using myh11-CreERT2::Rosa26Floxed-Stop-eYFP mice (unpublished data). Given the
availability of highly selective small molecule inhibitors of CDK8,105 these findings
provide the rationale for the translational study of CDK8 inhibitors on the prevention
and/or treatment of vascular lesion formation.
There are several issues requiring future studies. The mediator role of CDK8 in
vascular SMC dedifferentiation leading to vascular lesion formation needs to be verified
by genetic interrogations including mature vascular SMC specific CDK8 knockout
approach in vivo. The potential off-target effects of CDK8 inhibitors also need to be
evaluated via aforementioned genetic interrogations. Further investigation of these
subjects will lead to a better understanding of CDK8-mediated vascular remodeling and
dysfunction in pathological settings, therefore paving the way to develop novel
therapeutic approach to target CDK8 for vascular disease.
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Figure 4.1. Peri-vascular delivery of Senexin A is a mediator of AKT-c-MYC signaling
and SMC dedifferentiation. Male adult C57BL/6J mice (n=20) were subjected to sham or
complete carotid artery ligation with perivascular delivery of vehicle control or Sen A (30
µM/L) after 3 days. Two pools of carotid arteries (n=10 for each pool of each group)
were subjected to Western blot analysis as indicated (upper panel). Lower left panel is the
semi-quantified analysis of immunblots (n=4).
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Figure 4.2. Peri-vascular delivery of Senexin A significantly inhibited SMC accumulation
in the NI. Male adult C57BL/6J mice (n=10) were subjected to sham or complete carotid
artery ligation with perivascular delivery of vehicle control or Sen A (30 µM/L) for 28
days. A. Characterization of complete ligation-induced neonitima formation in the carotid
artery. B. αSMA expression in unligated and ligated carotid arteries of C57BL/6J mice
(n=10) at 28 days after operation was analyzed by confocal microscopy. The
representatives of αSMA staining are from 20 sections (n=4, 5 sections from each mouse)
from confocal microscopy. Veh, vehicle; Sen A, senexin A; CTL, contralateral unligated
carotid arteries.
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Figure 4.3. Peri-vascular delivery of Senexin A significantly inhibited NI. Male adult
C57BL/6J mice (n=10) were subjected to sham or complete carotid artery ligation with
perivascular delivery of vehicle control or Sen A (30 µM/L) for 28 days. Upper panel is
the representative H&E staining and lower panel shows the quantified NI area using
Image J Pro software.

76

Figure 4.4. The potential role of CDK8/AKT/GSK3β/c-MYC stabilization signaling axis
in mediating vascular SMC dedifferentiation and lesion formation. CDK8 is a critical
mediator of SMC dedifferentiation at least partly by facilitating the AKT-mediated
inhibition of GSK3β to stabilize c-MYC, thereby inducing dedifferentiation and vascular
lesion formation.
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CHAPTER 5
SUMMARY AND CONCLUSIONS
Occlusive vascular disease, characterized by abnormal proliferation and
accumulation of vascular SMCs in the vascular lesion, is one of the most common causes
of morbidity and mortality in USA.62 Upon disease or injury mature and quiescent
vascular SMCs undergo dedifferentiation which is characterized by a downregulation of
SMC-specific contractile markers, and a concomitant with an increase in cell
proliferation, migration, and ECM secretion, thereby leading to vascular lesion
formation.63–69 However, the mechanisms regulating the process of SMC
dedifferentiation remain unclear. The current study provides novel findings of a potential
role of CDK8 in SMC dedifferentiation. We also characterized the molecular
mechanisms through which CDK8 regulates SMC dedifferentiation, as well as the
pathophysiological relevance of CDK8 in vivo. We hypothesized that CDK8 is a critical
mediator in SMC dedifferentiation and vascular lesion formation.
For Aim 1,we demonstrated for the first time that CDK8 is normally expressed in
endothelial cells and vascular SMCs, thus suggesting that CDK8 is expressed under
normal physiological conditions in the vasculature. Moreover, CDK8 was shown to be
upregulated in dedifferentiating vascular SMCs, suggesting that CDK8 may play a role in
the pathological process of vascular disease. CDK8 inhibition was able to regulate all
three events by promoting increased proliferation, migration and ECM secretion as well
as promoting a synthetic phenotype.

78

For Aim 2, we identified a novel signaling axis of CDK8-AKT activation-GSK3β
inhibition-c-MYC stabilization in mediating SMC dedifferentiation. We uncovered that:
activation of CDK8 promotes the activation AKT to suppress GSK3β-mediated
phosphorylation of c-MYC at Thr58 for proteasomal degradation in RASMCs; CDK8
activates AKT to suppress GSK3β-mediated c-MYC degradation thereby promoting
RASMC dedifferentiation; and CDK8 kinase activity is critical for its association with
AKT thereby activating AKT and AKT-driven signaling in vascular SMCs.
For Aim 3, we demonstrated that inactivation of CDK8 led to the suppression of
vascular SMC dedifferentiation with typical synthetic phenotypes including increased
proliferation, migration, and ECM secretion in vitro. Secondly, we established that
inactivation of CDK8 inhibited SMC accumulation in NI.
In conclusion, our results demonstrate that CDK8 is a critical mediator of vascular
SMC dedifferentiation at least partly by facilitating the AKT-mediated inhibition of
GSK3β to stabilize c-MYC, thereby contributing to NI formation. Therefore, targeting
CDK8 may be a novel therapeutic approach for the treatment of occlusive vascular
disease due to the abnormal growth of vascular SMCs.
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APPENDIX A. PATIENT MEDICAL HISTORY
Table A.1. Tissue sections of arteries were prepared from autopsy organ specimens of
humans with a cardiovascular disease history.
Specimen #

Sex

Age

Disease history

Arterial occlusion

14607

Male

97

Hypertension; Prostate
cancer

Left coronary artery (moderate
atherosclerosis); Left circumflex
coronary artery (mild to moderate
atherosclerosis); Left anterior
descending coronary artery (mild to
moderate atherosclerosis)

14608

Male

60

Septic shock;
Disseminated
intravascular coagulation

Right coronary artery (mild
atherosclerosis); Left anterior
descending coronary artery (mild
atherosclerosis)

14609

Male

71

Coronary artery disease;
Bypass graft 2015;
Acute Myocardial
Infarction (left ventricle
interventricular septum)

Left anterior ventricle circumflex
coronary artery (sever atherosclerosis);
Left anterior descending coronary
artery (sever acute and chronic
atherosclerosis); Left posterior ventricle
posterior descending coronary artery
(sever atherosclerosis)

14612

Male

73

Chronic heart failure

Aorta (mild atherosclerosis)

14613

Female

71

Hypertension;
Myocardial rupture

Aorta (mild to moderate
atherosclerosis)

14610

Female

80

Hypertension; Asthma;
Lung (squamous cell
carcinoma)

Right coronary artery (minimal to mild
atherosclerosis)
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